Antibody-drug conjugates, genomics, and more: Key trends at the JP Morgan Healthcare Conference

[ipopba/Adobe Stock]

The 2024 JPMorgan Healthcare Conference showcased the resilience and innovation driving the biotech sector, even as the sector has recently grappled with financial headwinds such as declining IPOs, layoffs, and tightening cash reserves. Companies are tightening operations while still pushing forward in developing novel technologies like machine learning for drug discovery, cell and gene therapies, synthetic biology, and unlocking large-scale genomic edits. The CDMO market is also showing signs of renewed growth in early 2024, with opportunities in areas such as advanced therapeutics, oncology, and injectables.

Biotech resilience emerging as a theme, but ‘flawless execution’ a need

“JPM underscored the resilience of biotechs amid economic challenges, emphasizing strategic priorities like bringing assets into the clinic and an unwavering commitment to timelines,” said M…

Read more
  • 0

Anti-obesity drugs to command a $44 billion market by 2030

As obesity rates continue to soar across the globe, analysts anticipate that the market for anti-obesity drugs will skyrocket in the coming years. Goldman Sachs projects the market to be worth $44 billion by 2030. That’s an almost 16-fold expansion from its valuation of approximately $2.82 billion in 2022.

Jenny Chang, portfolio manager with Goldman Sachs Asset Management, highlighted the potential of the drug class, which includes Novo Nordisk’s Ozempic (semaglutide) and Wegovy (also semaglutide), as well as Eli Lilly’s tirzepatide. “Some 42% of Americans are obese, and the economic toll is staggering,” she said in a recent video. The investment firm noted that obesity costs the American healthcare system are in the ballpark of $170 billion annually. Furthermore, the obesity epidemic could drag down global GDP by $4 trillion by 2035.

Echoing this sentiment, JPMorgan Chase & Co. believes Novo Nordisk could capture almost half o…

Read more
  • 0